BioCentury | Apr 2, 2020
Product Development

COVID-19 roundup: EMA seeks to rein in chloroquine use; plus cash for CEPI, WHO’s SOLIDARITY grows, CytoDyn, EUSA, Chembio, PCR Biosystems and more

...emergency IND. CytoDyn shares gained $0.40 (15%) to $3.07 Wednesday. EUSA Pharma Ltd. said Sylvant siltuximab...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

...The Papa Giovanni XXIII Hospital has initiated an observational case-control clinical trial, SISCO, of Sylvant siltuximab...
BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

...deal with U.K.-based EUSA Pharma Ltd., BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) gained Chinese rights to Sylvant siltuximab...
...in milestones, plus royalties. BeiGene will be responsible for the products' local development and registration. Sylvant...
...subtilisin/kexin type 9; PD-1 (PDCD1; CD279) - Programmed cell death 1 BioCentury Staff inclisiran (aln-pcssc, pcsk9si) Sylvant, siltuximab (CNTO 328) Rubraca...
BioCentury | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

...have identified an early biomarker predicting idiopathic multicentric Castleman’s disease (iMCD) patients’ responses to Sylvant siltuximab...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Gastrointestinal

...and has the compound in Phase III testing for dermatitis. Johnson & Johnson markets Sylvant siltuximab...
BioCentury | Jul 20, 2018
Company News

EUSA acquires global rights to J&J's Sylvant

...Johnson & Johnson (NYSE:JNJ) granted EUSA Pharma Ltd. (Hemel Hempstead, U.K.) worldwide rights to Sylvant siltuximab...
...NYSE:JNJ), New Brunswick, N.J. EUSA Pharma Ltd., Hemel Hempstead, U.K. Business: Cancer Jaime De Leon Sylvant, siltuximab (CNTO 328) EUSA...
BioCentury | Apr 10, 2018
Distillery Therapeutics

Cancer

...Next steps include testing undisclosed IL-6 inhibitors in glioblastoma patients. Johnson & Johnson markets Sylvant siltuximab...
BioCentury | Feb 22, 2018
Targets & Mechanisms

Molecular mentality

...anti-IL-6 mAb sirukumab is in Phase II testing for major depressive disorder, and its Sylvant siltuximab...
BioCentury | Feb 7, 2018
Distillery Therapeutics

Cancer

...IL-1α or IL-6 inhibitors in models of HER2-positive breast cancer. Johnson & Johnson markets Sylvant siltuximab...
BioCentury | Jul 21, 2017
Strategy

Accessing miracles

...followed by another dose of Actemra. Fourth-line therapy includes other IL-6 inhibitors such as Sylvan siltuximab...
Items per page:
1 - 10 of 42